Protagonist Therapeutics에 대한 매도 수량은 투자자에게 Protagonist Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Protagonist Therapeutics (NASDAQ:PTGX) 주식, 공매도 수량 보고

Protagonist Therapeutics

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

이 중형주들은 지난주에 가장 좋은 성과를 냈습니다. 당신의 포트폴리오에 있나요? 1. D-웨이브 퀀텀(NYSE:QBTS)의 주식은 회사가 4분기 수주가 1억 8,300만 달러로 전년 대비 502% 증가했다고 보고한 후 95.95% 상승했다.

D-웨이브 퀀텀과 아이온큐 등 지난주 급등한 중형주 8종목 (3월 10일-3월 14일)

ASTSpaceMobile.Screenshotvideo

ASTS

BEAM

CLDX

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

PEGA

VKTX

VSAT

다음은 지난주 큰 폭의 상승세를 보인 6개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? AST 스페이스모바일(NASDAQ:ASTS)의 주가는 회사가 첫 5개의 상용 위성을 성공적으로 완료하면서 47.88% 상승했다.

비아샛 및 AST 스페이스모바일은 지난주 최고 성과를 보여준 6개 중형주 중 일부 (7월 21일-7월 27일)

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics Inc

2025 Guidance (revised)
<ul>
<li>Sales of $1.88 billion to $1.95 billion (reduced from $1.95 billion to $2.05 billion)</li>
<li>Adjusted diluted earnings per share of $1.85 - $2.05 (reduced from $2.05 to $2.25)</li>
<li>Free cash flow of approximately $190 million (reduced from greater than $220 million)</li>
<li>Capital expenditures less than $90 million (reduced from less than $100 million)</li>
<li>Effective tax rate of 21% (unchanged)</li>
</ul>
Note that guidance does not include the potential impact of any new tariffs announced after March 31, 2025

Guidance

UPDATE: Hexcel Revises FY25 Adj. EPS From $2.05-$2.25 To $1.85-$2.05 Vs $2.12 Est.; Revenue From $1.95B-$2.05B To $1.88B-$1.95B Vs $1.988B Est.

Dividends

VALU

Value Line Announces Quarterly Dividend Increase From $0.28 To $0.325 Per Share

Financial Outlook — Reiterating Fiscal Year 2026 Guidance
We are reiterating our fiscal year guidance, reflecting our confidence in the Company's strategic execution, operational resilience, and market positioning. Fiscal year 2026 guidance reflects our best estimates given expected market conditions for the full year, lower interest expense, an annualized effective tax rate of 25% and excludes M&amp;A and any federal regulatory changes that may emerge.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">FY2026 Guidance(1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.625 - $1.725 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$360 - $400 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$5.50 - $6.10</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="2" rowspan="1">&nbsp; FY2026 Guidance Assumptions:</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">a.</td>
<td colspan="1" rowspan="1">Excludes the impact of any future acquisitions.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">b.</td>
<td colspan="1" rowspan="1">Management defines adjusted earnings per share to exclude intangible asset amortization, acquisition expenses, transaction related expenses, certain legal settlements and accruals, and certain expenses related to non-recurring events from the reported GAAP measure.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">c.</td>
<td colspan="1" rowspan="1">Assumes EBITDA margin range of 27 - 32% for the Metal Coatings segment and 17% - 22% for the Precoat Metals segment.</td>
</tr>
</tbody>
</table>
</figure>

AZZ Reiterates FY26 EPS $5.50-$6.10 Vs $5.84 Est.; Revenue $1.625B-$1.725B Vs $1.679B Est.

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) reported quarterly earnings of $0.98 per share which met the analyst consensus estimate. This is a 5.38 percent increase over earnings of $0.93 per share from the same period last year. The company reported quarterly sales of $351.88 million which missed the analyst consensus estimate of $368.55 million by 4.52 percent. This is a 3.99 percent decrease over sales of $366.50 million the same period last year.

Earnings

Earnings Misses

AZZ Q4 Adj $0.98, Inline, Sales $351.88M Miss $368.55M Estimate

General

CMBM

Cambium Networks Hit With Nasdaq Deficiency Notice

TD Securities analyst Aaron Macneil maintains TC Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TRP#TSX">TRP</a>) with a Buy and raises the price target from C$73 to C$74.

Price Target

Analyst Ratings

TSX:TRP

TD Securities Maintains Buy on TC Energy, Raises Price Target to C$74

Home Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBCP#NASDAQ">HBCP</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.14 by 20.18 percent. This is a 20.18 percent increase over earnings of $1.14 per share from the same period last year.

Earnings Beats

HBCP

Home Bancorp Q1 EPS $1.37 Beats $1.14 Estimate

CADE

Cadence Bank Q1 2025 Adj. EPS $0.71 Up From $0.62 YoY, Sales $448.539M Up From $437.694M YoY

HOUSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Weatherford International plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) ("Weatherford" or the "Company") today announced it has signed a strategic Memorandum of Understanding (MOU) with AIQ, the Abu Dhabi-based artificial intelligence (AI) champion developing innovative solutions for the energy sector. This partnership is set to bring transformative efficiency to energy production, leveraging advanced automation, data-driven insights, and the power of AI technology.
The collaboration aims to integrate Weatherford's world-class software and hardware solutions, including the Modern Edge suite, Unified Data Model, and WFRD Software Launchpad, with AIQ's robust AI-driven systems. By combining these advanced tools, Weatherford and AIQ will enable operators to optimize their production workflows, reduce downtime, and significantly enhance operational efficiency across global oil and gas facilities.

WFRD

Weatherford International Signs Strategic MoU With AIQ To Accelerate Efficiency In Energy Production

Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.78 by 0.56 percent.

Western Alliance Q1 2025 GAAP EPS $1.79 Beats $1.78 Estimate

Billionaire entrepreneur Mark Cuban is raising concerns about a trend he thinks could hurt the U.S. economy in a big way: American investors increasingly looking overseas to cut costs.
<h2 class="wp-block-heading">&#8220;Insane&#8221; Strategy Could Undercut U.S. Innovation</h2>
In a recent Bluesky <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lmphvqxhwc2z">post</a>, Cuban called out what he sees as an emerging shift in global investing. More and more so-called investment experts are urging people to diversify their portfolios beyond U.S. borders, including into international stock markets, private companies and startups.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Invest in the future of digital engagement: <a href="https://www.benzinga.com/money/vatom-adv">Own a piece of the $100 billion Metaverse for just $500</a>.</li>
</ul>
Cuban says this isn't just about spreading risk—it's also about saving money. He warns that investors are now looking to export talent and funnel money into startups in countries where labor and operational costs are a fraction of what they are in the U.S.&nbsp;
&#8220;It&#8217;s possible to export your smartest people, hire overseas, and fund their business at a fraction of costs you face here. Insane,&#8221; Cuban wrote.
He believes that trend could result in fewer opportunities for U.S.-based innovators and entrepreneurs as capital flows elsewhere. Bottom line is that instead of helping the domestic economy, as Trump's tariffs were supposedly meant to do, U.S. money could end up fueling business ecosystems in other countries.
Trending: <a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">This investment company boasts a 33.85% internal rate of return (IRR) for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.</a>
<h2 class="wp-block-heading">Tariffs, Layoffs and Economic Pain</h2>
Cuban&#8217;s comments come as he continues to <a href="https://www.benzinga.com/news/25/04/44826725/mark-cuban-says-trumps-tariffs-caused-companies-to-panic-buy-inventory-resulting-in-cost-cutting-and-job-losses">criticize President Donald Trump's</a> latest round of tariffs and aggressive government spending cuts. In a recent <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lmf7rp3ym22n">post</a>, Cuban said these policies have already pushed companies to panic-buy inventory ahead of tariff deadlines, tying up cash that could have been used for growth or hiring.
&#8220;That&#8217;s cash taken from being able to invest or hire,&#8221; he wrote. &#8220;In fact, they probably cut costs and jobs as a result.&#8221;
He added that if the tariffs stick around and the Department of Government Efficiency keeps slashing federal jobs and funding, the economic fallout could be worse than the 2008 financial crisis.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">&#8220;Shock and Awful&#8221; Policy Moves</h2>
<a href="https://www.benzinga.com/news/25/03/44575557/mark-cuban-says-if-they-replaced-elon-musk-with-him-hes-still-try-to-make-government-smaller-by-cutting-a-lot-of-people">Cuban isn&#8217;t against smaller government</a>, but he slammed the current approach. &#8220;Trying to cut the size of government… and cutting a lot of people for better or worse, comes with the territory,&#8221; he <a href="https://www.youtube.com/watch?v=di3AqpoLI74">said</a> on &#8220;The Lincoln Project Podcast.&#8221; &#8220;But if there&#8217;s no plan behind shock and awe, it&#8217;s just shock and awful.&#8221;
He pointed to real-world consequences, such as job losses in small towns where government agencies are major employers. He also criticized recent <a href="https://www.benzinga.com/25/04/44775706/when-i-hear-our-politicians-say-were-not-gonna-touch-social-security-i-dont-believe-them-seniors-are-worried-about-doge-changes">Social Security changes</a>, which require seniors to <a href="https://www.benzinga.com/news/25/03/44498325/gonna-be-some-upset-seniors-at-town-halls-says-mark-cuban-he-calls-doge-social-security-actions-a-back-door-move-to-cut-payments">confirm their payments online</a>. &#8220;What an amazing back-door way to cut payments! Gonna be some upset seniors at town halls!&#8221;
He believes the current economic strain is a direct result of campaign promises becoming policy—and he's urging voters not to be surprised when those decisions hit home.
For Cuban, the issue isn't just about policy. It's about what kind of economy the U.S. wants to build: one that invests in its own people, or one that outsources talent and opportunity in the name of cutting costs.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

'Insane'—Mark Cuban Thinks US Investors Will Start Exporting Talent And Funding Startups Abroad To Cut Costs

TD Securities analyst Menno Hulshof maintains Imperial Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#TSX">IMO</a>) with a Hold and lowers the price target from C$94 to C$92.

TSX:IMO

TD Securities Maintains Hold on Imperial Oil, Lowers Price Target to C$92

Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 12.64%. Currently, Hilton Worldwide Holdings has a market capitalization of $49.22 billion. 
Buying $1000 In HLT: If an investor had bought $1000 of HLT stock 10 years ago, it would be worth $3,264.99 today based on a price of $204.59 for HLT at the time of writing.
<h3>Hilton Worldwide Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745267421_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Hilton Worldwide Holdings Stock In The Last 10 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ALEAF">Aleafia Health</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALEAF#OTC">ALEAF</a>) shares closed up 900.00% at $0.0001</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 66.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 37.50% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 8.11% at $0.97</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 7.13% at $0.24</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 4.48% at $6.30</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 3.90% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 43.62% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 26.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 16.99% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 16.25% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 13.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 13.25% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 12.92% at $0.85</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 9.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 9.29% at $1.08</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.27% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/EHC">Encompass Health</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) shares closed down 7.00% at $96.12</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 6.84% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 6.79% at $5.22</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 6.76% at $8.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 6.32% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 5.66% at $0.63</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 5.41% at $4.20</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 5.38% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 4.82% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.81% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 4.55% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 3.36% at $3.74</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed down 3.01% at $146.61</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

BBRRF

BLOZF

CLSH

CNBX

CNTMF

CPHRF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CWBHF

CXXIF

FFNTF

FUAPF

GNLN

GRWG

GTBIF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

MRMD

OILFF

RMHB

RSSFF

SOLCF

TCNNF

TGIFF

UGRO

Cannabis Stock Movers For April 21, 2025

FLXS

Flexsteel Industries Sees Q4 Sales In The Range Of $109M - $116M; Projects FY25 Sales Between $435M And $442M

WIIM

MEDP

Medpace Holdings shares are trading lower. The company reported Q1 financial results.

Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.43 by 13.95 percent. This is a 15.91 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $456.50 million which missed the analyst consensus estimate of $475.73 million by 4.04 percent. This is a 3.35 percent decrease over sales of $472.30 million the same period last year.

Hexcel Q1 2025 Adj EPS $0.37 Misses $0.43 Estimate, Sales $456.50M Miss $475.73M Estimate

Real Estate

FCPT

Corners Property Trust Acquires A Chuy's Property For $2.9M

Activist <a href="https://www.benzinga.com/topic/dan-loeb" target="_blank" rel="noreferrer noopener">investor </a><a href="https://www.benzinga.com/topic/dan-loeb" target="_blank" rel="noreferrer noopener">Dan Loeb</a>‘s Third Point LLC held 1.78 million shares in Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/news/large-cap/25/01/43195763/dan-loebs-third-point-capitalizes-on-tsms-ai-expansion" target="_blank" rel="noreferrer noopener">as of December 2024</a>.
The chip manufacturer&#8217;s share price dipped nearly 27 year to date. Compared that to VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>), which fell over 23%, and the S&amp;P 500's year-to-date decline of roughly 12.1%.
Earnings &amp; Other Notable Events:
<ul>
<li>On April 17, Taiwan Semiconductor reported first-quarter net sales of $25.53 billion (839.25 billion New Taiwanese Dollars). That&#8217;s up 41.6% year-over-year (Y/Y), topping the<a href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" target="_blank" rel="noreferrer noopener"> analyst consensus estimate of $23.92 billion</a>.</li>
<li>The demand for advanced&nbsp;processor node technologies for artificial intelligence applications fueled the result.</li>
<li>Taiwan Semiconductor&nbsp;guided for second-quarter&nbsp;2025 revenue of $28.4 billion to $29.2 billion versus the $26.79<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">&nbsp;billion analyst estimate</a>. It expects a gross margin of 57% to 59% and operating profit margins of 47% to 49%.</li>
<li>Taiwan Semiconductor&#8217;s CFO said, so far, there has been no noticeable shift <a href="https://www.benzinga.com/markets/25/04/44881525/tsmc-confident-amid-trump-tariff-turmoil-ceo-cc-wei-says-no-change-in-customer-behavior-despite-nvidia-h20-chip-curbs" target="_blank" rel="noreferrer noopener">in customer behavior in response</a> to U.S. tariffs.</li>
<li>Notably, China's new rule reportedly&nbsp;exempts chips designed&nbsp;by U.S. companies but manufactured in Taiwan from its 125% retaliatory tariffs. This rule has also exempted TSMC.</li>
<li>Also, the company disclosed in its 2024 annual report that the&nbsp;U.S. semiconductor technology&nbsp;embargo challenged its ability to ensure <a href="https://www.benzinga.com/government/regulations/25/04/44895326/taiwan-semiconductor-confronts-challenges-of-us-chips-sanction-on-china" target="_blank" rel="noreferrer noopener">complete compliance with the rules</a>.</li>
<li>Goldman Sachs&nbsp;analyst&nbsp;Kinger Lau, CFA, said delisting fears for Chinese American Depositary Receipts (ADRs) are rising again, driven by escalating trade tensions and new policy guidance from U.S. officials, including President&nbsp;Donald Trump‘s America First Investment Policy and Treasury Secretary&nbsp;Scott Bessent&#8216;s statement that &#8220;everything is on the table&#8221; <a href="https://www.benzinga.com/government/regulations/25/04/44868280/us-listed-chinese-stocks-face-250-billion-forced-selling-risk-as-delisting-fears-emerge-what-investors-need-to-know" target="_blank" rel="noreferrer noopener">in the response to China&#8217;s retaliatory tariffs</a>.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44698171/trumps-tariff-push-sends-financials-lower-loebs-portfolio-take-a-hit" target="_blank" rel="noreferrer noopener">Tariffs Test Loeb's Financial Picks: Third Point Adjusts Bets As Markets Brace For Economic Blowback</a></li>
</ul>
Image: Shutterstock

Tech

Dan Loeb's Bet On Taiwan Semiconductor Looks Strong As Q1 Results Top Expectations

Meiwu Technology shares are trading higher after the company announced it regained Nasdaq compliance.

Press Releases

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Comments

Protagonist Therapeutics

매도 수량

Protagonist Therapeutics (NASDAQ:PTGX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌